BCPC

Balchem Corp. 10-K Summary: Fiscal Year Ended December 31, 1999

Business Context and Reporting Period

This report covers the fiscal year ended December 31, 1999, for Balchem Corporation, a Maryland-based company incorporated in 1967. The company develops, manufactures, and markets specialty performance ingredients for the food, feed, and medical sterilization industries. Operations are divided into two segments: Encapsulated Products (micro-encapsulation for food and animal health) and Specialty Products (repackaging and marketing of specialty gases like ethylene oxide for medical sterilization). As of March 1, 2000, the company employed approximately 116 persons.

Key Financial Metrics

Segment Performance: Specialty Products generated $19.8 million in sales and $5.6 million in operating income. Encapsulated Products generated $9.8 million in sales but reported an operating loss of $600,000 due to lower margins and increased R&D expenses.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 3% ($961,000) driven by a 6% increase in the Encapsulated Products segment and a 2% increase in Specialty Products.
• Profitability: Net earnings rose 5% to $3.1 million. Operating income increased to $5.0 million from $4.8 million.
• Debt Reduction: Long-term debt decreased significantly by $2.5 million (from $3.75 million to $1.25 million), reducing net interest expense from $164,000 to $111,000.
• Segment Divergence: While the Specialty Products segment remained highly profitable, the Encapsulated Products segment shifted from a profit of $176,000 in 1998 to a loss of $600,000 in 1999, primarily due to product mix changes in international markets and heavy investment in the new "Reashure" product.
• Capital Allocation: The company repurchased 128,400 shares of common stock for $943,000 under a new buyback program and paid a dividend of $0.05 per share.

Outlook, Risks, and Management Commentary

Outlook and New Products: Management launched "Reashure," an encapsulated choline for ruminant animals, in late 1999 following successful trials. Capital expenditures are projected to be approximately $840,000 for 2000. The company maintains a $2,000,000 line of credit with no outstanding borrowings.

Key Risks and Contingencies:

• Customer Concentration: One customer, Griffith Micro Science, Inc., accounted for 15.6% of net sales in 1999. Loss of this customer could have a material adverse effect.
• Regulatory Compliance: The company's ability to sell ethylene oxide depends on EPA re-registration. Testing is complete, and the EPA anticipates completing the review in 2001. The product has no known equally effective substitute.
• Environmental Liability: The company is monitoring a former waste drum site in Slate Hill, NY. Cleanup was completed in 1996, but monitoring continues through 1999. Historical monitoring costs are less than $10,000 per year.
• Raw Material Volatility: The company faces risks regarding raw material price fluctuations, though it generally passes these costs to customers.

Investor Verification Checklist

• EPA Re-registration Status: Verify the timeline for the EPA's final decision on the ethylene oxide re-registration, as this product is critical to the Specialty Products segment.
• Customer Concentration: Monitor the relationship with Griffith Micro Science, Inc., which represents over 15% of total revenue.
• Encapsulated Segment Turnaround: Assess whether the investment in "Reashure" and other new products will reverse the operating loss in the Encapsulated Products segment.
• Debt Covenants: Review the amended term loan agreement (maturing 2004) for financial ratio requirements that could restrict future dividends or borrowing.
• Stock Repurchase Activity: Track the execution of the remaining authorized share repurchases (up to 1 million shares total) and their impact on earnings per share.